Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H3B-6527 是一种在 FGF19 驱动的肝细胞癌中有效且选择性的 FGFR4 抑制剂,具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 662 | 现货 | ||
2 mg | ¥ 980 | 现货 | ||
5 mg | ¥ 1,730 | 现货 | ||
10 mg | ¥ 2,970 | 现货 | ||
25 mg | ¥ 5,230 | 现货 | ||
50 mg | ¥ 7,380 | 现货 | ||
100 mg | ¥ 9,980 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,170 | 现货 |
产品描述 | H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity. |
体外活性 | H3B-6527, a highly selective covalent FGFR4 inhibitor, through structure-guided drug design. Studies in a panel of 40 HCC cell lines and 30 HCC PDX models showed that FGF19 expression is a predictive biomarker for H3B-6527 response. Moreover, coadministration of the CDK4/6 inhibitor palbociclib in combination with H3B-6527 could effectively trigger tumor regression in a xenograft model of HCC[1].?FGFR4 is frequently overexpressed in ESCC tissue and cell lines. in vitro assays have shown that blocking FGFR4 by a specific blocker, H3B-6527, significantly decreases proliferation, invasion, and migration, and alters epithelial-mesenchymal transition markers in ESCC cells. In addition, FGFR4 blockade is associated with the induction of apoptosis and affects PI3K/Akt and MAPK/ERK pathways[2]. |
细胞实验 | Immunohistochemistry and Western blotting were used to detect FGFR4 expression in ESCC samples and cell lines. Cell counting kit-8, and clonogenic, transwell, flow cytometric, and tumor xenograft in nude mice assays were utilized to determine the effect of blocking FGFR4 in proliferation, invasion, migration, and apoptosis of ESCC cells[2]. |
分子量 | 629.54 |
分子式 | C29H34Cl2N8O4 |
CAS No. | 1702259-66-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.3 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5885 mL | 7.9423 mL | 15.8846 mL | 39.7115 mL |
5 mM | 0.3177 mL | 1.5885 mL | 3.1769 mL | 7.9423 mL | |
10 mM | 0.1588 mL | 0.7942 mL | 1.5885 mL | 3.9712 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
H3B-6527 1702259-66-2 Angiogenesis Tyrosine Kinase/Adaptors FGFR H3B6527 H-3B-6527 H3B 6527 Inhibitor inhibitor inhibit